Biotech 2050 Podcast

Alok Tayi, Rahul Chaturvedi

jean@biotech2050.com

Booking Overview

Biotech 2050 focuses on how biotech will evolve over the next 50 years, using forward-looking insight grounded in real leadership experience. The show is a strong fit for PR outreach to executives and physician-scientists who can connect long-range innovation themes with company strategy, clinical development, and industry disruption.

Metrics

Episodes: 260

Frequency: Irregular

Rating: 4.7/5.0

Estimated listeners: 1k-10k

Gender skew: Neutral

Location: USA

30s Ad: 34 - 39, 60s Ad: 41 - 45

Contact Information

jean@biotech2050.com

Host

Alok Tayi - Host of Biotech 2050; leads conversations tying biotech disruption to long-term industry direction and leadership perspectives.

Rahul Chaturvedi - Host of Biotech 2050; guides discussions at the intersection of biotech innovation, leadership, and human capital themes within the industry.

Booking Intelligence

Booking Requirements

medium

Typical Credentials:

Biotech/pharma leadership (CEO/COO/CFO/executive), physician-scientists (MD/PharmD), and founders/board-level operators with demonstrated involvement in drug development (often FDA-approved or late-stage pipeline). Strong ability to speak to long-horizon industry disruption (50-year framing), not just a narrow therapeutic area.

Required Achievements:

Runs a clinical-stage biotech or leads a major addiction/therapeutics-focused company, Led R&D and/or company development through regulatory milestones (often FDA approvals), Authored or formally recognized for leadership development work, Significant senior roles (e.g., C-suite, board director, former CMO/CEO), Experience with funding, scaling, and/or M&A outcomes

Recent Guest Discussions

Barry Quart - Asthma/copd Innovation; Il-4 Receptor Biology; Scaling And Leadership In Publicly Traded Biotech; Geopolitics And Global Strategy In Drug Discovery.

Cary Claiborne - Precision-genetics Approach To Alcohol Use Disorder; Biotech Strategy For Addiction Medicine; Phase III Trial Design With Ai-driven Simulations; Expansion To Related Impulse-driven Conditions.

Sheila Gujrathi - Biotech Innovation And Deal Environment; Leadership And Inclusive Networks For Women In Science; Lessons From Building And Scaling Biotech Companies; Experience Guiding An Acquisition By Lilly.

Recent Topics

Biotech, Drug Development, Healthcare, Precision Medicine, Clinical Trials, Leadership, Innovation, Pharmaceuticals, Genetics, Health Policy

Episodes

Here's the recent few episodes on

Biotech 2050 Podcast

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

May 13, 2026

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry. From starting as a pharmacist in the UK to pivoting from R&D into commercial leadership at Johnson & Johnson, rising through Bristol Myers Squibb, and ultimately stepping into her first biotech CEO role at Aca...

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

April 16, 2026

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment. With over 30 years in pharmaceutical R&D and nine FDA-approved drugs to his name, Barry shares a rare insider perspective on building and scaling biotech companies—from pioneering HIV therapies that resh...

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

March 06, 2026

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM 2026 in San Francisco, host Alok Tayi speaks with Cary Claiborne, CEO of Adial Pharmaceuticals, about a new precision-medicine approach to tackling one of the world’s most widespread and undertreated conditions: alcohol use disorder. Cary shares the personal and professional journey that brough...

Get your clients booked on top podcasts

Try us risk free with a FREE 3 days trial.

Start Your Free Trial

Join hundreds of PR teams using Podseeker to pitch and land bookings